JP2006520813A5 - - Google Patents

Download PDF

Info

Publication number
JP2006520813A5
JP2006520813A5 JP2006507972A JP2006507972A JP2006520813A5 JP 2006520813 A5 JP2006520813 A5 JP 2006520813A5 JP 2006507972 A JP2006507972 A JP 2006507972A JP 2006507972 A JP2006507972 A JP 2006507972A JP 2006520813 A5 JP2006520813 A5 JP 2006520813A5
Authority
JP
Japan
Prior art keywords
pab
aze
pharmaceutically acceptable
formula
combination product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006507972A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006520813A (ja
Filing date
Publication date
Priority claimed from GBGB0306615.6A external-priority patent/GB0306615D0/en
Application filed filed Critical
Publication of JP2006520813A publication Critical patent/JP2006520813A/ja
Publication of JP2006520813A5 publication Critical patent/JP2006520813A5/ja
Pending legal-status Critical Current

Links

JP2006507972A 2003-03-22 2004-03-19 低分子量トロンビン阻害剤のコレステロール低下療法における使用 Pending JP2006520813A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0306615.6A GB0306615D0 (en) 2003-03-22 2003-03-22 New use
PCT/SE2004/000417 WO2004082702A1 (en) 2003-03-22 2004-03-19 Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy

Publications (2)

Publication Number Publication Date
JP2006520813A JP2006520813A (ja) 2006-09-14
JP2006520813A5 true JP2006520813A5 (https=) 2007-05-17

Family

ID=9955311

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006507972A Pending JP2006520813A (ja) 2003-03-22 2004-03-19 低分子量トロンビン阻害剤のコレステロール低下療法における使用

Country Status (17)

Country Link
US (1) US20060183692A1 (https=)
EP (1) EP1608311B1 (https=)
JP (1) JP2006520813A (https=)
KR (1) KR20050114237A (https=)
CN (1) CN1761479A (https=)
AT (1) ATE475417T1 (https=)
AU (1) AU2004222409B2 (https=)
BR (1) BRPI0408522A (https=)
CA (1) CA2517191A1 (https=)
DE (1) DE602004028348D1 (https=)
ES (1) ES2346969T3 (https=)
GB (1) GB0306615D0 (https=)
MX (1) MXPA05010159A (https=)
NO (1) NO20054285L (https=)
NZ (1) NZ542505A (https=)
WO (1) WO2004082702A1 (https=)
ZA (1) ZA200507614B (https=)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1237518B (it) * 1989-11-24 1993-06-08 Renato Conti Eparine supersolfatate
JP3140790B2 (ja) * 1996-04-23 2001-03-05 メルク エンド カンパニー インコーポレーテッド ピラジノン系トロンビン阻害薬
WO1998011896A1 (en) * 1996-09-18 1998-03-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
AR023510A1 (es) * 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
GB0014136D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
US6462021B1 (en) * 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AU2003270861A1 (en) * 2002-10-02 2004-04-23 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
US7470538B2 (en) * 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method

Similar Documents

Publication Publication Date Title
JP2010509379A5 (https=)
JPWO2020123827A5 (https=)
JP2002501887A5 (ja) アルツハイマー病の治療用の薬剤の製造のための血漿トリグリセライドレベル低下剤の使用
WO2001081312A3 (en) Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
CA2429979A1 (en) Treatment of statin side effects
IL175716A (en) 2- (4-Bromo- or 4-Methyl-Phenylamino) -6-Oxo-1,6-Dihydropyridines and their use in drug preparation
RU2002123350A (ru) Дипептиднитрильные ингибиторы катепсина К
JP2004521894A5 (https=)
JP2004115534A5 (https=)
JP2011505347A5 (https=)
JP2007534702A5 (https=)
JP2008537930A5 (https=)
RU2007147346A (ru) Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний
RU2007147344A (ru) Новые производные 2-азетидинона для лечения гиперлипидемических заболеваний
RU99101081A (ru) Режим введения ингибиторов н+, к+-атфазы
RU2007147340A (ru) Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний
JP2004315496A5 (https=)
RU2007118727A (ru) Ингибиторы mif
CA2474262A1 (en) Short-acting sedative hypnotic agents for anesthesia and sedation
RU2007147338A (ru) Новые производные 2-азетидинона и их применение в качестве ингибиторов всасывания холестерина для лечения гиперлипидемии
JP2006503805A5 (https=)
RU2007116987A (ru) Новые соединения
JP2010518016A5 (https=)
JP2006520813A5 (https=)
JP2003509494A5 (https=)